HLB bioStep Co.,Ltd. (KOSDAQ:278650)
South Korea · Delayed Price · Currency is KRW 3,150.00
+35.00 (1.12%)
At close: Jun 5, 2026
HLB bioStep Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 73,958 | 74,050 | 58,169 | 52,814 | 86,277 | 64,403 |
Other Revenue | - | - | - | - | - | 0 |
| 73,958 | 74,050 | 58,169 | 52,814 | 86,277 | 64,403 | |
Revenue Growth (YoY) | 22.89% | 27.30% | 10.14% | -38.78% | 33.96% | 10.05% |
Cost of Revenue | 18,635 | 18,143 | 17,339 | 17,533 | 32,343 | 23,147 |
Gross Profit | 55,323 | 55,907 | 40,830 | 35,281 | 53,934 | 41,256 |
Selling, General & Admin | 57,011 | 57,709 | 46,407 | 31,623 | 40,986 | 26,527 |
Research & Development | 911.59 | 936.39 | 824.35 | 811.99 | 978.14 | 1,165 |
Amortization of Goodwill & Intangibles | 692.3 | 692.1 | 492.52 | 63.28 | 70.28 | 30 |
Other Operating Expenses | 483.64 | 889.67 | 858.76 | 712.99 | 709.09 | 696.32 |
Operating Expenses | 64,024 | 64,546 | 53,877 | 36,467 | 48,625 | 32,249 |
Operating Income | -8,701 | -8,639 | -13,048 | -1,186 | 5,309 | 9,007 |
Interest Expense | -2,385 | -2,051 | -858.96 | -3,471 | -4,246 | -184.7 |
Interest & Investment Income | 770.51 | 817.3 | 1,821 | 1,469 | 1,401 | 85 |
Earnings From Equity Investments | -4,616 | -4,460 | 1.68 | -488.74 | -1,659 | 3,608 |
Currency Exchange Gain (Loss) | -13.8 | -10.3 | 4.16 | 32.3 | 13.81 | 9.9 |
Other Non Operating Income (Expenses) | 33.09 | 33.86 | 233.81 | 561.71 | -2,767 | 775.48 |
EBT Excluding Unusual Items | -14,912 | -14,309 | -11,845 | -3,083 | -1,947 | 13,300 |
Gain (Loss) on Sale of Investments | 1,719 | 1,714 | 182.73 | 3,418 | 534.22 | -440.56 |
Gain (Loss) on Sale of Assets | 13.38 | 16.35 | 135.08 | -9.47 | -23.37 | -33.11 |
Asset Writedown | -4,948 | -4,948 | - | - | -907.99 | - |
Pretax Income | -18,127 | -17,527 | -11,528 | 325.66 | -2,345 | 12,827 |
Income Tax Expense | 2,409 | 2,728 | -1,835 | 379.9 | -1,462 | 1,295 |
Earnings From Continuing Operations | -20,536 | -20,255 | -9,693 | -54.24 | -882.73 | 11,532 |
Net Income to Company | -20,536 | -20,255 | -9,693 | -54.24 | -882.73 | 11,532 |
Minority Interest in Earnings | 1,260 | 1,293 | 1,128 | -109.81 | -125.27 | -501.4 |
Net Income | -19,277 | -18,962 | -8,564 | -164.04 | -1,008 | 11,031 |
Net Income to Common | -19,277 | -18,962 | -8,564 | -164.04 | -1,008 | 11,031 |
Net Income Growth | - | - | - | - | - | 32.87% |
Shares Outstanding (Basic) | 18 | 17 | 17 | 15 | 14 | 14 |
Shares Outstanding (Diluted) | 18 | 17 | 17 | 15 | 14 | 14 |
Shares Change (YoY) | -44.94% | 0.68% | 9.45% | 9.59% | 0.02% | 1.35% |
EPS (Basic) | -1085.34 | -1121.56 | -510.00 | -10.69 | -72.00 | 809.35 |
EPS (Diluted) | -1085.34 | -1121.56 | -510.00 | -10.69 | -72.00 | 790.00 |
EPS Growth | - | - | - | - | - | 31.42% |
Free Cash Flow | -4,299 | 1,113 | -20,594 | 1,189 | 1,587 | -11,135 |
Free Cash Flow Per Share | -242.07 | 65.84 | -1226.35 | 77.53 | 113.33 | -795.47 |
Gross Margin | 74.80% | 75.50% | 70.19% | 66.80% | 62.51% | 64.06% |
Operating Margin | -11.77% | -11.67% | -22.43% | -2.25% | 6.15% | 13.98% |
Profit Margin | -26.06% | -25.61% | -14.72% | -0.31% | -1.17% | 17.13% |
Free Cash Flow Margin | -5.81% | 1.50% | -35.40% | 2.25% | 1.84% | -17.29% |
EBITDA | -3,926 | -3,908 | -8,345 | 2,290 | 9,412 | 12,033 |
EBITDA Margin | -5.31% | -5.28% | -14.35% | 4.33% | 10.91% | 18.68% |
D&A For EBITDA | 4,774 | 4,731 | 4,703 | 3,476 | 4,103 | 3,026 |
EBIT | -8,701 | -8,639 | -13,048 | -1,186 | 5,309 | 9,007 |
EBIT Margin | -11.77% | -11.67% | -22.43% | -2.25% | 6.15% | 13.98% |
Effective Tax Rate | - | - | - | 116.66% | - | 10.09% |
Advertising Expenses | - | 91.38 | 178.58 | 152.13 | 340.63 | 256.01 |